Figure S1 - An Influenza A/H1N1/2009 Hemagglutinin Vaccine Produced in Escherichia coli
Schematic representation of an immunoassay used to validate the preferential biological affinity of the recombinant protein for antibodies present in serum of patients infected with influenza A H1N1/2009. (A) Anti-histidine antibodies were fixed to the surface of 96 well immunoassay microplates. (B) After blocking with a commercial agent, a solution of protein HA63–286-RBD was added to each well. (C) In comparative experiments, serum samples (1∶50 dilution) from positive and negative volunteers were added; left panel illustrates a scenario with a higher concentration of specific influenza antibodies. (D) Addition of a peroxidated anti-IgG human antibody to specifically bind the retained serum antibodies. The addition of peroxidase substrate enables the enzymatic peroxidation with an associated proportional development of colour.
(1.82 MB TIF)